Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CinnaGen Co","sponsor":"Vaxine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"IRAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by CinnaGen Co

    Menu

    CinnaGen Co

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CinnaGen Co

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Iran
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CinnaGen Protein Subunit Covid-19 Vaccine Phase III Results Likely Within Two Months

              Details:

              SpikoGen features the SARS-CoV-2 spike protein and Vaxine’s own Advax-SM adjuvant. The placebo-controlled SpikoGen trial has coprimary endpoints investigating the occurrence of symptomatic Covid-19 and severe Covid-19, with both endpoints.

              Lead Product(s): SARS-CoV-2 Recombinant Spike Protein,Advax-SM

              Therapeutic Area: Infections and Infectious Diseases Product Name: SpikoGen

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Vaxine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 16, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY